BioPharma Clinical Trials
TenNor Therapeutics Secures Over 300 Million RMB in Series E Funding to Advance Novel Antibiotics for Drug-Resistant Infections
TenNor Therapeutics, a clinical stage company dedicated to developing new therapies to address unmet needs in infectious diseases, announced today the init...
October 17, 2024 | News
SONIRE Therapeutics Secures FDA Breakthrough Device Designation for Advanced HIFU Therapy in Pancreatic Cancer
SONIRE Therapeutics Inc. (hereinafter referred to as "SONIRE"), based in Tokyo, Japan, announces that its self-developed next-generation HIFU (Hi...
October 17, 2024 | News
Endogenex Achieves Key Clinical Milestone with First Patient Enrolled in ReCET™ Study for Type 2 Diabetes Treatment
Achieving a Significant Clinical Milestone in Assessing the ReCET™ System as a Groundbreaking Treatment for Type 2 Diabetes Endogenex, Inc., a clini...
October 16, 2024 | News
PharmAbcine Receives Safety Approval for 4mg Dose in Phase 1 Trial of PMC-403, Paving the Way for Multiple Ascending Dose Study
Safety Review Committee (SRC) approves single ascending dose 4mg cohort in Phase 1 trial of PMC-403, preparing for multiple ascending dose 4 mg cohort. ...
October 15, 2024 | News
Australian Clarity Pharmaceuticals Receives Positive FDA Feedback for Pivotal Phase III Trial of 64Cu-SAR-bisPSMA in Prostate Cancer
United States Food and Drug Administration (U.S. FDA) provided positive feedback on a pivotal Phase III trial for 64Cu-SAR-bisPSMA diagnostic in pro...
October 15, 2024 | News
Dizal Receives Fourth Breakthrough Therapy Designation for Sunvozertinib in EGFR Exon20ins NSCLC
Fourth Breakthrough Therapy Designation for sunvozertinib in NSCLC with EGFR exon20ins Dizal (SSE:688192), a biopharmaceutical company committed to d...
October 14, 2024 | News
Akeso Biopharma Secures $250 Million in Share Placement to Accelerate Global Clinical Trials
Expediting International Clinical Trials for Pivotal Products Key Participants Include International Long-Term and Healthcare Funds Akeso Biopharma annou...
October 14, 2024 | News
Genentech's Itovebi™ Wins FDA Approval for HR-Positive Breast Cancer, Doubling Progression-Free Survival in PIK3CA-Mutated Cases
– Approval is based on Phase III INAVO120 results, showing the ItovebiTM (inavolisib)-based regimen more than doubled progression-free sur...
October 11, 2024 | News
Pierre Fabre and Scorpion Therapeutics Dose First Patient in Phase I/II Trial of PFL-241/STX-241, a Promising 4th Generation EGFR Inhibitor
PFL-241/STX-241 is a highly selective, and potentially best-in-class fourth generation epidermal growth factor receptor ("EGFR") inhibitor One of two EGFR...
October 09, 2024 | News
Ascentage Pharma’s APG-2449 Tyrosine Kinase Inhibitor Cleared for Two Registrational Phase III Studies in NSCLC Patients
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet med...
October 08, 2024 | News
Telix Pharmaceuticals Doses First Patient in Phase II Trial for Advanced Kidney Cancer Imaging Agent
Telix Pharmaceuticals Limited announces that the first patient has been dosed in a Phase II trial exploring the clinical utility of Telix's first-in-class ...
October 04, 2024 | News
Arcus and AstraZeneca Partner to Evaluate Novel Combination Therapy for Advanced Renal Cell Carcinoma
Arcus and AstraZeneca to evaluate their respective molecules in combination to establish a potential first- and best-in-class treatment for clear c...
October 03, 2024 | News
Hetero and Gilead Sciences Partner to Expand Global Access to Lenacapavir for HIV Treatment and Prevention
Non-exclusive voluntary license agreement enables the manufacture and distribution of lenacapavir for HIV prevention and treatment of heavily treatment-exp...
October 03, 2024 | News
Doer Biologics Begins Phase 2 Study of First-in-Class Tri-Agonist DR10624 for Severe Hypertriglyceridemia
Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and...
October 01, 2024 | News
Most Read
- BioPharma Trends 2025: 25 Key Insights Shaping Asia Pacific's Future
- Driving Oncology Forward: 25 Companies Redefining Antibody-Drug Conjugates (ADCs) in 2025
- 25 Biopharma Leaders Shaping a Sustainable 2025: Innovation Meets Environmental Responsibility
- 25 Leading AI Companies to Watch in 2025: Transforming Drug Discovery and Precision Medicine
- Mr. Brendan O’Callaghan Discusses Sanofi’s Singapore Modulus Facility: Advancing Biopharma Manufacturing and Pandemic Preparedness
- Shaping the Future of PCV Care: Insights from Roche’s Stefan Scheidl on the SALWEEN Trial
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Shaping a Health Innovation Hub: Alessandro Falcone Reflects on JLABS Singapore’s Milestone Year and Future Goals
Bio Jobs
- Avance Clinical Appoints Jessica Han as Director of Asian Operations, Strengthening Commitment to the Asian Market
- Bristol Myers Squibb Employees Cycle Coast-to-Coast to Raise $1 Million for Cancer Research
- Pfizer Australia Commits $150M to Upgrade Melbourne Facility, Bolstering Global Fight Against Antimicrobial Resistance
- SMi Systems Appoints Dr. Stefan Hamill as Vice President of Strategy to Drive Commercialisation and Growth
- Thermo Fisher Scientific Appoints William Hung as Senior Director and General Manager for Taiwan
- Cytiva Appoints Industry Veteran Pierre-Alain Ruffieux as Chief Operating Officer
News
